News

Immunosuppressive therapies, administered with or without acetylcholinesterase inhibitors, helped ease symptoms of ocular myasthenia gravis (MG), according to an analysis of medical records from several hospitals in Japan. Although treatment was associated with favorable outcomes, some symptoms persisted in more than half the treated patients. Still, immunotherapy, including corticosteroids,…

A rare case of myasthenia gravis (MG) that preceded the onset of autoimmune encephalitis (AE) — a type of autoimmune disease affecting the brain — was described in a recent case report. The 24-year-old man, who didn’t test positive for MG-associated antibodies, but did have two distinct types of…

For people with rare health conditions like myasthenia gravis (MG), navigating the U.S. health insurance system can be difficult, but there are many resources that can support patients. Challenges with accessing healthcare and advice about overcoming them were the main topics of the “Navigating Insurance Coverage” panel discussion…

Life with myasthenia gravis (MG) often means finding new ways to do things that used to be easy but now are more challenging. In a workshop at the MG Foundation of America (MGFA) National Patient Conference, a group of panelists discussed how MG has impacted them, and shared some…

For people with myasthenia gravis (MG) and other chronic diseases, it’s important to be proactive in learning how to best manage the condition and connect with others in the disease community. “The first thing I really need to let you know is that you’re the only person who can…

Maintaining a hopeful outlook is a vital part of managing myasthenia gravis (MG). Hope can help improve a person’ quality of life and may even modulate disease activity, according to Jeffrey Rosenfeld, MD, PhD, director of the Center for Restorative Neurology at Loma Linda University Health, who discussed the…

Treatment with rozanolixizumab — an investigational therapy being developed by UCB for generalized myasthenia gravis (gMG) — worked in a clinical trial to ease symptom severity for a subset of patients who were positive for muscle specific kinase (MuSK) antibodies. That’s according to analyses from the Phase…

The use of Ultomiris (ravulizumab) led to stronger reductions in generalized myasthenia gravis (gMG) symptoms for people who had been living with the disease for no more than two years, new analyses from the CHAMPION MG trial indicated. “Overall, our analysis suggests that treatment of gMG with [Ultomiris]…

Ultomiris (ravulizumab) treatment led to sustained reductions in generalized myasthenia gravis (gMG) symptom severity and acute clinical worsening events for more than a year, according to new analyses from the CHAMPION MG clinical trial and its open-label extension (OLE). The analyses were presented at the Muscular Dystrophy Association’s…

Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) in patients regardless of their disease length, treatment history, or acetylcholine receptor (AChR) antibody status, according to two new analyses from the ADAPT clinical trial and its open-label extension, ADAPT+. These findings serve to reinforce “the efficacy of efgartigimod…